Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 4,651 matching trials from the live ClinicalTrials.gov search.
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide), Placebo (cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Fresno, California • Los Alamitos, California + 19 more
Conditions
Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
Interventions
Deferoxamine, Deferiprone (L1)
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Conditions
Neuroendocrine Tumors
Interventions
68Ga-DOTATATE
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sirolimus in LAM

NCT00414648
Conditions
Lymphangioleiomyomatosis
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 7 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Conditions
Cholestatic Liver Disease
Interventions
Maralixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 3 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

NCT02620852
Conditions
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
Interventions
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 74 Years · Female only
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
Terminated Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

NCT03759678
Conditions
Ataxia Telangiectasia
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Recruiting Not applicable Interventional

Bright Ideas - CIN Feasibility Study

NCT04929899
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Bright Ideas - CIN Training
Behavioral
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
4 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Los Angeles, California • New Brunswick, New Jersey • Falls Church, Virginia
Conditions
Covid19
Interventions
mQFPD, organic brown rice
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 13 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Houston, Texas
Conditions
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
97
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Ipilimumab, Nivolumab, Paclitaxel, Positron Emission Tomography, Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
488
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more
Conditions
Bacterial Infections
Interventions
Eravacycline (TP-434)
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 4 more
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Conditions
Steno-occlusive Disease
Interventions
gadopiclenol, Gadoterate meglumine (Dotarem)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Conditions
Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions
Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Darcy Krueger
Other
Eligibility
1 Day to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 5 more
Conditions
ADHD
Interventions
Flashed Light Therapy, Videoconference-delivered Cognitive Behavioral Therapy
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Seizures
Interventions
Standardized seizure protocol, Conventional seizure protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 13 Years
Enrollment
6,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 17 more
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more